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Background: We assessed the surgical results along with the clinical and biological 
features of non-small cell lung cancer (NSCLC) patients with localized large tumors. 
Methods: The study population consisted of 86 NSCLC patients who underwent 
complete resection of tumors 5 cm or larger in diameter in stage IB (T2N0M0). We 
immunohistochemically assessed the expression of angiostatin and endostatin.  
Results: The median tumor size was 6.0 cm (range, 5–14 cm). The operative procedures 
used were lobectomy in 71 cases, bilobectomy in 8 cases, and pneumonectomy in 11 
cases. Fifty patients (58.1%) relapsed during the mean follow-up period of 33.6 ± 4.5 
months. The median disease-free interval (DFI) was 9 months. Of 44 recurrent patients 
whose DFI could be identified, 25 patients (56.8%) relapsed within 12 months after the 
operation. The overall 5- and 10-year survival rates were 42.0% and 24.2%, respectively. 
Multivariate analysis showed that the degree of pleural involvement and angiostatin 
expression within the tumor were independent prognostic indicators. The endostatin 
expression within tumors also had a weaker relationship with outcome. 
Conclusions: Long-term surgical results were poor and early relapse was common in 
this cohort. In addition to pleural involvement, the tumor-induced expression of 
angiostatin and endostatin merit further investigation to gain possible insights into 
selection of patients who will benefit from surgery as the first line treatment.  
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Introduction 
Surgery remains the mainstay treatment for localized non-small cell lung cancer 
(NSCLC) patients irrespective of the tumor size. As tumor size is crucial for the 
oncological outcome in NSCLC patients, the effects of surgical treatment are still 
uncertain in patients with large tumors. Although lung cancer is considered a surgically 
treatable disease in the relatively early stages, recent retrospective clinical assessment 
showed that a diameter of more than 5 cm is the threshold predicting poor prognosis in 
lung carcinoma, suggesting that the current staging system should be revised [1-4]. On 
the other hand, some investigators suggested that localized large tumors also include 
those with less metastatic potential[5]. However, the biological features specific to large 
tumors have not been clarified.  
 There have been a number of studies using the experimental metastasis paradigm in 
the areas of both basic and clinical research. Based on such studies, it has begun to 
become clear that the removal of the primary tumor occasionally results in stimulation 
of cancer cell proliferation in metastatic foci [6-9]. Interestingly, the inhibition of 
proliferation of these metastatic foci can be explained partly by the production of 
anti-angiogenic factors, such as angiostatin and endostatin [10,11]. These factors are 
both endogenous angiogenesis inhibitors, which are related to the inhibition of 
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metastatic growth by the primary neoplasms. From this specific oncological viewpoint, 
the appropriateness of removal of the primary tumor as the first line of treatment 
remains an open question, especially in patients with large primary tumors. On a 
hypothesis that large tumors have a high risk of systemic micrometastasis and produce 
inhibitory anti-angiogenic factors, we performed the present retrospective review to 
assess surgical results by highlighting angiostatin and endostatin expression in NSCLC 
patients with large tumors in the relatively early stage of disease.  
 
Patients and Methods 
Patients  
 From January 1981 to December 2004, a total of 1,436 NSCLC patients underwent 
pulmonary resection at Kanazawa University Hospital. Of these patients, 283 (19.7%) 
had bulky primary tumors 5 cm or larger in diameter, and complete resection of the 
primary tumor could be achieved in 259 patients. Among these 259 patients, 86 (72 men 
and 14 women) patients in pathological stage IB (T2N0M0) according to the TNM 
classification [12] who had undergone complete resection with systematic 
lymphadenectomy were included in this retrospective review. Lymph node biopsy 
through mediastinoscopy or thoracoscopy was performed selectively in 19 patients with 
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clinical N2 diagnosis based on the results of CT and 201Tl or FDG-PET scan. None of 
the patients underwent any preoperative induction treatment. The degree of pleural 
involvement was classified pathologically as follows: p0, no invasion; p1, tumor 
invasion reached the visceral pleura but not beyond; p2, tumor invasion penetrated the 
visceral pleura but not the parietal pleura. In this study, N1 nodal station number was 
designated according to Naruke’s map [13]. Written informed consent was obtained 
from all patients. 
 
Immunohistochemical assessment of angiostatin, endostatin, and VEGF-A  
 Resected tumor specimens could be collected from 83 patients. After reviewing the 
hematoxylin and eosin-stained slides of the tumor specimens, we selected blocks of the 
invasive edge in the tumor area. Paraffin-embedded tumor tissues were cut into 
consecutive sections 4 µm thick, deparaffinized, and subjected to immunohistochemical 
staining using the labeled streptavidin-biotin method, as described previously [14]. The 
primary antibodies used in the present study were a rabbit polyclonal antibody to 
angiostatin (Oncogene Research Products, Cambridge, MA) diluted 150-fold [15], a 
rabbit polyclonal antibody to endostatin (Lab Vision Corp., Fremont, CA), and a rabbit 
polyclonal antibody to VEGF (Santa Cruz Biotechnology Inc., Santa Cruz, CA) diluted 
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100-fold. Negative controls were stained using all reagents except the primary 
antibodies. As positive controls for angiostatin and endostatin, we used formalin-fixed, 
paraffin-embedded human melanoma and tonsil tissues, respectively, according to the 
manufacturers’ recommendations. 
The immunoreactivities were graded as (-), (+), and (++) according to the intensity of 
the tumor cells: (-) represents positive staining of 0%–10% of the total area, (+) 
represents 10%–50% positive staining, and (++) represents the strongest staining of 
more than 50% at ×200 magnification. For assessment of angiostatin and endostatin 
expression, tumors with (-) staining were classified as negative. For assessment of 
VEGF-A expression, tumors with the strongest staining were defined as overexpressing 
VEGF-A [14]. The positivity of these markers was evaluated by two independent 
viewers without knowledge of the clinical factors. 
 
Statistical analysis 
Survival time was measured from the date of surgery. The disease-free interval (DFI) 
was calculated for patients who showed relapse and was defined as the interval between 
time of lung surgery and clinical or radiographic demonstration of the first recurrence. 
Survival curves were plotted by the Kaplan-Meier method and univariate comparisons 
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were performed by the log-rank test. Zero time was the date of surgical treatment. The 
effects of age, gender, pathological type (squamous vs. other), location of primary tumor 
(right vs. left and upper lobe vs. lower lobe), nodal status (N0 vs. N1), pleural 
involvement (p0/1 vs. p2), adjuvant systemic chemotherapy, VEGF-A, angiostatin, and 
endostatin on overall survival and DFI were assessed. Age and tumor size were 
classified as being in the high or low group relative to the median value. For 
multivariate analysis, Cox’s proportional hazards regression was used and factors with 
p<0.10 were included in the final model. Associations between variables were analyzed 
with the χ2 test. The Mann-Whitney U test for differences in mean values was used for 
comparison of nominal data. Mean values are shown ± the standard errors. 
 
Results 
 The basic clinical and pathological features of the patients are shown in Table 1. The 
patients ranged in age from 45 to 84 years (median age, 69.0). The median tumor size 
was 6.0 cm (range, 5–14 cm). The pathological types were as follows: 50 squamous cell 
carcinomas, 31 adenocarcinomas, 3 adenosquamous cell carcinomas, and 2 large cell 
carcinomas. The operative procedures used were lobectomy in 71 cases, 
pneumonectomy in 7 cases, and bilobectomy in 8 cases. Postoperative adjuvant 
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chemotherapy was performed in 24 patients. In-hospital mortality for all 86 patients was 
0.01% (1/86). Information about overall survival and DFI could be obtained for all 
patients and for 44 patients, respectively. In the mean follow-up period of 33.6 ± 4.5 
months (range, 1–146 months), 50 patients (58.1%) relapsed. Of the 44 recurrent 
patients whose DFI could be identified, 25 (56.8%) relapsed within 12 months after 
surgical removal of the primary tumors. The median DFI was 9 months (range, 2–105 
months). Among the 22 patients whose recurrent pattern could be identified clearly, 
distant and local recurrence developed in 19 and 3 cases, respectively. In the total cohort, 
the overall 5- and 10-year survival rates were 42.0% and 24.2%, respectively. The 
disease-free survival rate at 5 years was only 10.3%. With respect to the pleural 
involvement, the patients with p2 showed significantly poorer survival and shorter 
period of DFI as compared to those with p0–1 (Fig. 1).  
 VEGF-A, angiostatin, and endostatin antigens were identified mainly in the 
cytoplasm of tumor cells (Fig. 2). These antigens were also identified in vascular 
endothelial cells, and angiostatin antigen was also found in some smooth muscle cells 
and lymphatic cells. 
 The percentage of patients with VEGF-A overexpression was 75.9% (63 of 83 
patients). Four cases were classified as (-) and 16 cases were classified as (+). On the 
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other hand, the percentages of patients positive for angiostatin and endostatin 
expression were 13.3% (11 of 83 patients) and 54.2% (45 of 83 patients), respectively.  
In univariate analysis, pleural involvement (p2), negativity for angiostatin, and 
negativity for endostatin had significant negative impact on overall survival (Table 2). 
While the overall 5- and 10-year survival rates of angiostatin-positive or 
endostatin-positive patients were 47.0% and 29.1%, respectively, those of 
angiostatin-negative and endostatin-negative patients were 21.6% and 0%, respectively 
(p=0.0049)(Fig. 3). Although the number of patients was limited (n=7), the 10-year 
survival rate of angiostatin-positive and endostatin-positive patients was 83.3%. 
Multivariate analysis showed that pleural involvement and angiostatin were independent 
prognostic indicators on overall survival (Table 3).  
 
Comments 
 Currently, surgical resection represents the standard first line of treatment for localized 
NSCLC in the early stages irrespective of tumor size. However, earlier studies indicated 
that the surgical outcome of NSCLC with large tumors more than 5 cm in diameter is 
poor. Carbone and associates [2] reported that 5-year survival rate of 111 NSCLC 
patients with T2 tumors more than 5 cm in diameter was 35.1%. In their series, the 
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significant survival difference based on this threshold remained in N0 and N2-3 status. 
In the assessment of 60 pN0-NSCLC patients with a tumor size greater than 5 cm, 
Takeda et al. [4] reported that 5-year survival rate after surgery was 46.6%. Cangir et al. 
[3] also found that the 5-year survival rate of patients with tumors larger than 5 cm in 
diameter was significantly poorer than that of patients with tumors measuring 3.1–5 cm 
in diameter when patients at various stages were included. In our series highlighting 
localized pT2N0M0 patients with a tumor size of 5 cm or larger in diameter, we 
similarly found poor outcomes with a 5-year survival rate of 42.0%. Consistent with 
previous data, the surgical results of patients with large tumors 5 cm or greater in 
diameter were poor after the initial operation even in those at the earliest stage.  
Although it is still not clear which population among these localized NSCLC with 
large tumors would benefit from surgery, the findings of the present study have some 
implications for the selection of patients that may benefit from surgical resection. 
Considering the possibility that the lack of tumor-induced growth inhibitory factors may 
accelerate residual micrometastatic foci after removal of the primary site, we performed 
immunohistochemical assessment of the expression of two noble markers, angiostatin 
and endostatin. These two biological markers appeared to be associated with surgical 
outcomes in the present study. Angiostatin is a proteolytic fragment of plasminogen, 
 10 
which was found originally in a primary Lewis lung carcinoma [10]. There has been 
only one previous report of immunohistochemical determination of angiostatin 
expression in lung cancer, in which the results obtained in 143 NSCLC patients in stage 
I-IIIA indicated that angiostatin expression within the tumor is a favorable prognostic 
factor [15]. Our observations regarding the relationship between angiostatin expression 
and patients outcome were consistent with the findings of this previous study. Further, 
while the percentages of patients with tumors positive for angiostatin were 24% 
(34/143) in the total patient population in various stages and 24% (11/45) in patients in 
stage I-II in this previous study, the percentage of patients positive for angiostatin 
expression was only 13.3% (11/83) in our series using the same antibody under the 
same experimental conditions. Therefore, the expression of angiostatin within the tumor 
may be suppressed in large lung cancer lesions. On the other hand, endostatin was 
isolated originally from murine hemangioendothelioma [11] and identified as the 
C-terminal fragment of its precursor, collagen XVIII [16]. With regard to endostatin 
expression in lung cancer, the presence of its precursor, collagen XVIII, in lung cancer 
cells was confirmed previously [17]. Notably, some investigators from the same 
institute reported previously that its expression in lung cancer tissue was associated with 
tumor progression and poor outcomes in assessment of patients at various stages [17,18]. 
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The endostatin expression in tumor tissue was also reported to be associated with tumor 
grade and poor outcome in other neoplasms [19]. Interestingly, in hepatocellular 
carcinoma, collagen XVIII expression decreases with both increasing tumor size and 
tumor progression [20]. Considering these conflicting phenomena, the relationship 
between endostatin expression within the tumor and patient outcome may be altered 
according to the tumor type and their phase or stage of progression. The presence or 
absence of micrometastases will also inevitably affect this relationship. In the present 
study, we found that both of these anti-angiogenic factors were actually expressed in 
some tumors. In our series of large tumors 5 cm or more in diameter, although the 
percentage of tumors positive for endostatin expression was relatively high as compared 
to that of tumors positive for angiostatin expression, both endostatin and angiostatin 
expression at the primary site were associated with preferable outcome on overall 
survival. Therefore, it is unlikely that loss of tumor-induced angiostatin/endostatin 
expression at the primary site after removal of the tumor affects early relapse. Our 
findings support the idea that the presence of these anti-angiogenic factors within the 
tumor is associated with preferable outcome after removal of the primary tumor as the 
first line of treatment.  
We also found that the degree of pleural invasion was associated with surgical results, 
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consistent with previous findings reported by Carbone and colleagues [2]. The 
appropriateness of initial operation in patients with pleural invasion must be determined 
carefully in patients with the disease. 
 In conclusion, long-term surgical results were not satisfactory and the frequency of 
early relapse was high in this cohort. Pleural involvement was determined as a 
significant independent prognostic indicator of overall survival. Further, 
angiostatin/endostatin expression within tumors should be investigated further to gain 
possible insights into the selection of patients who will benefit from surgery as the first 
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Figure Legends 
Figure 1. Kaplan-Meier overall survival plots for 120 T2N0-1M0 non-small cell lung 
cancer patients with large tumors 5 cm or greater in diameter stratified by 
pleural involvement. The degree of pleural involvement was classified 
pathologically as: p0, no invasion; p1, tumor invasion reached the visceral 
pleura but not beyond; p2, tumor invasion penetrate the visceral pleura but 
not the parietal pleura. The patients with p2 showed significantly poorer 
survival as compared to those with p0–1 (p=0.008). The survival curves are 
combined with lines representing the 90% confidence interval. 
Figure 2. Examples of immunohistochemical staining for (A) angiostatin and (B) 
endostatin. Cytoplasmic staining was positive in tumor cells. (Original 
magnification, ×400.) 
Figure 3. Kaplan-Meier overall survival plots of T2N0M0 non-small cell lung cancer patients with 
large tumors 5 cm or greater in diameter stratified by the expression of angiostatin and 
endostatin. The difference was statistically significant (p=0.0049). The survival curves 




Table 1. Patient Demographics 
Characteristics      Values           
No. of patients       86 
Gender 
  Male        72  
  Female         14 
Median age (years)         69    
Median tumor size (cm)        6.0    
Location-1 
  Right         51    
  Left         35    
Location-2 
  Upper lobe        39    
  Middle lobe          1        
  Lower lobe        46    
Histology 
  Adenocarcinoma        31   
  Squamous cell carcinoma       50    
  Others           5           
Pleural involvement 
  Negative (p0)       52 
  Reached visceral pleura but not beyond (p1)    22 
  Penetrate visceral pleura but not the parietal pleura (p2)    7 
  Unknown        5 
Adjuvant chemotherapy        24    
Operative procedures 
  Lobectomy   71 
  Pneumonectomy    7 






Table 2. Univariate Analysis of Prognostic Factors 
 
Factors      Hazard ratio  p Value  
           (95% CI) 
 
Age     0.824 (0.624-1.077) 0.158 
Gender     1.372 (0.954-2.137) 0.091 
Tumor size    0.859 (0.659-1.129) 0.271 
Histology (Adenocarcinoma vs others) 1.066 (0.818-1.401) 0.636 
Pleural involvement    3.496 (1.420-7.411) 0.008 
Adjuvant therapy    1.071 (0.822-1.407) 0.609 
Location(1)(rt vs. lt)   1.228 (0.936-1.634) 0.137 
Location(2)(upper lobe vs. lower lobe) 1.280(0.971-1.682)  0.078 
VEGF-A     1.310 (0.699-2.678) 0.412 
Angiostatin    7.550 (2.689-31.583) <0.00001 



















 Table 3. Multivariate Analysis of Prognostic Factors 
 
 
Factors              Favorable  Unfavorable Hazard ratio (95% CI) p Value 
Pleural involvement p0-1     p2  2.727 (1.096-5.887) 0.032 
Angiostatin  Positive   Negative 7.222 (2.172-44.794) 0.0003 
Endostatin  Positive   Negative 1.701 (0.976-2.997) 0.060   
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